|0.1608|| -0.0092 / -5.41%|
Taxus Cardium Pharmaceuticals Group, Inc. is regenerative therapeutics company . The company focuses on the late-stage clinical and development of regenerative medicine therapeutics. Its product candidates include Generx, an interventional cardiology, angiogenic gene therapy product candidate designed for the treatment of cardiac microvascular insufficiency due to increasing coronary artery disease; and Excellagen, an acellular biological skin substitute designed as a wound care product for the treatment of chronic non-healing diabetic foot, venous and pressure ulcers. The company was founded by Christopher J. Reinhard and Tyler M. Dylan-Hyde on December 22, 2003 and is headquartered in San Diego, CA.
|Christopher J. Reinhard||Chairman, President, CEO, CFO, Treasurer & CAO|
|Gabor M. Rubanyi||Chief Scientific Officer|
|Lois A. Chandler||Vice President-Biologics Development|
|Duane M. Linstrom||Secretary|